Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease

Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

(2012) Michael D. Kappelman et al.   DIGESTIVE DISEASES AND SCIENCES

Response to biologic therapy in Crohnʼs disease is improved with early treatment: An analysis of health claims data

(2012) David T. Rubin et al.   INFLAMMATORY BOWEL DISEASES

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

(2010) Asher Kornbluth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996-2002

(2008) Lisa J. Herrinton et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial

(2008) Edward V. Loftus et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults

(2008) Michael D. Kappelman et al.   GASTROENTEROLOGY

The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients

(2008) Mary E. Charlson et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET